4,4-dimethyl-7-nitro-3,4-dihydro-2H-naphthalen-1-one oxime | 1022950-40-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4,4-dimethyl-7-nitro-3,4-dihydro-2H-naphthalen-1-one oxime
• 英文别名: N-(4,4-dimethyl-7-nitro-2,3-dihydronaphthalen-1-ylidene)hydroxylamine
• CAS: 1022950-40-8
• 化学式: C₁₂H₁₄N₂O₃
• 分子量: 234.255
• InChiKey: LAOKAZWBLHWMQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,4-dimethyl-7-nitro-3,4-dihydro-2H-naphthalen-1-one oxime 在 polyphosphoric acid 作用下， 反应 17.0h， 以47%的产率得到5,5-dimethyl-8-nitro-1,3,4,5-tetrahydro-benzo[b]azepin-2-one
  参考文献：
  名称：

  Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors

  摘要：

  The HGF-c-Met signaling axis is an important paracrine mediator of epithelial-mesenchymal cell interactions involving the regulation of multiple cellular activities including cell motility, mitogenesis, morphogenesis, and angiogenesis. Dysregulation of c-Met signaling (e. g., overexpression or increased activation) is associated with the development of a wide range of tumor types; thus, inhibiting the HGF-c-Met pathway is predicted to lead to anti-tumor effects in many cancers. Elaboration of a 2-arylaminopyrimidine scaffold led to a series of potent c-Met inhibitors bearing a C4-2-amino-N-methylbenzamide group. Specifically, a series of C2-benzazepinone analogs demonstrated potent inhibition of c-Met in enzymatic and cellular assays. Kinase selectivity could be tuned by varying the nature of the alkyl group on the benzazepinone nitrogen. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.045
• 作为产物：
  描述：

  3,4-二氢-4,4-二甲基-7-硝基-萘-1(2H)-酮 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 以91%的产率得到4,4-dimethyl-7-nitro-3,4-dihydro-2H-naphthalen-1-one oxime
  参考文献：
  名称：

  Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors

  摘要：

  The HGF-c-Met signaling axis is an important paracrine mediator of epithelial-mesenchymal cell interactions involving the regulation of multiple cellular activities including cell motility, mitogenesis, morphogenesis, and angiogenesis. Dysregulation of c-Met signaling (e. g., overexpression or increased activation) is associated with the development of a wide range of tumor types; thus, inhibiting the HGF-c-Met pathway is predicted to lead to anti-tumor effects in many cancers. Elaboration of a 2-arylaminopyrimidine scaffold led to a series of potent c-Met inhibitors bearing a C4-2-amino-N-methylbenzamide group. Specifically, a series of C2-benzazepinone analogs demonstrated potent inhibition of c-Met in enzymatic and cellular assays. Kinase selectivity could be tuned by varying the nature of the alkyl group on the benzazepinone nitrogen. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.045